Literature DB >> 6122004

Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia.

H G Prentice, H A Blacklock, G Janossy, K F Bradstock, D Skeggs, G Goldstein, A V Hoffbrand.   

Abstract

Seventeen patients who received allogeneic bone-marrow transplants from matched or slightly mismatched (in four patients) siblings were observed for at least 60 days or until acute graft-versus-host disease (GvHD) developed. All donor marrows after preliminary manipulation were incubated with 1 mg of the murine monoclonal antibody OKT3 before infusion in an attempt to deplete them of immunocompetent T lymphocytes (opsonisation). In three of the seventeen patients acute GvHD of grade II or greater developed. Two of these patients died, but they had disseminated cytomegalovirus infection as well as GvHD. Eleven patients showed no evidence of acute GvHD, and four had transient limited skin rashes (grade I GvHD). Opsonisation of T lymphocytes has reduced the incidence of severe acute GvHD in this unit from 79% in an earlier group of 14 patients to 18% when added to prophylactic methotrexate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6122004     DOI: 10.1016/s0140-6736(82)92619-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

Review 1.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

Review 3.  Graft-versus-host disease of the intestine.

Authors:  G J Cox; G B McDonald
Journal:  Springer Semin Immunopathol       Date:  1990

Review 4.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

5.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

6.  An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells.

Authors:  P L Tazzari; L Barbieri; M Gobbi; A Dinota; S Rizzi; A Bontadini; A Pession; S Tura; F Stirpe
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Authors:  Mark Wunderlich; Ryan A Brooks; Rushi Panchal; Garrett W Rhyasen; Gwenn Danet-Desnoyers; James C Mulloy
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

8.  Natural killer (NK) cells and graft-versus-host disease (GVHD): no correlation between the NK cell levels and GVHD in the murine P----F1 model.

Authors:  K Varkila; M Hurme
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

Review 9.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  In vivo inhibition by a monoclonal antibody to CD4+ T cells of humoral and cellular immunity in sheep.

Authors:  H S Gill; D L Watson; M R Brandon
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.